CTC Alternative Strategies’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$207K Buy
+3,600
New +$207K 0.3% 78
2025
Q3
Sell
-5,700
Closed -$264K 97
2025
Q2
$264K Sell
5,700
-4,500
-44% -$221K 0.23% 118
2025
Q1
$622K Buy
+10,200
New +$595K 0.76% 31
2024
Q3
Sell
-10,034
Closed -$417K 77
2024
Q2
$417K Buy
+10,034
New +$449K 0.18% 133
2013
Q3
Sell
-16,500
Closed -$737K 106
2013
Q2
$737K Buy
+16,500
New +$716K 0.2% 37

Other funds holding BMY

CTC Alternative Strategies's BMY Position: Q2 2026 in Review

CTC Alternative Strategies opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 3,600 shares worth $207K. The stake represents 0.3% of the portfolio and ranks #78 among its holdings. This is a return to the name: CTC Alternative Strategies previously reported a position in BMY as recently as Q2 2025.

CTC Alternative Strategies first reported a position in BMY in Q2 2013 and has held it in 5 quarters since. The position peaked at $737K in Q2 2013. 2,524 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • CTC Alternative Strategies held 3,600 shares of Bristol-Myers Squibb worth $207K as of Q2 2026.
  • Bristol-Myers Squibb was a new CTC Alternative Strategies position in Q2 2026.
  • Bristol-Myers Squibb made up 0.3% of CTC Alternative Strategies's portfolio in Q2 2026, its #78 holding.
  • CTC Alternative Strategies first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 5 quarters since.
  • CTC Alternative Strategies's Bristol-Myers Squibb position peaked at $737K in Q2 2013.
  • 2,524 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on CTC Alternative Strategies's 13F filing for Q2 2026, filed 13 Aug 2026.